Clinical trials: Total-Body Irradiation
Lymphoma, B-cell Lymphoma
Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab
This phase II trial is studying how well giving fludarabine and cyclophosphamide together with total-body irradiation and rituximab works in treating patients with B-cell lymphoma or chronic lymphocytic leukemia who are…
- Conditions
- Lymphoma, B-cell Lymphoma, Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT00946023
- Testing
- Fludarabine, Cyclophosphamide, Total body irradiation
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Leukemia
High-Dose Chemotherapy Followed by Total-Body Irradiation and Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00002788
- Testing
- filgrastim, cyclophosphamide, dexamethasone
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Fred Hutchinson Cancer Center
T-Cell Lymphocytic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
BuCy Vs. TBICy for Allo-HSCT in T-ALL Patients
T-cell acute lymphoblastic leukemia (T-ALL), a hematological malignant neoplasm of immature T cells, accounting for a morbidity of 10-15% among pediatric and 20-25% among adult patients of ALL.
- Conditions
- T-Cell Lymphocytic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Total Body Irradiation, Chemotherapy
- Trial name
- NCT06673459
- Testing
- TBICy, BuCy
- Where
- China
- Volunteers
- 430 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Acute Leukemia, MDS
BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)
This study is being done to see if the addition of a targeted form of radiation to standard conditioning regimen will increase the amount of cancer cells that are killed off in the bone marrow and reduce the chances that your…
- Trial name
- NCT04187105
- Testing
- Conditioning regimen with half-matched (haploidentical) stem cell transplant
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Illinois Chicago
Non-Small-Cell Lung Cancer
A Study of SBRT Combined With Puterizumab in Intrapulmonary Metastasis From NSCLC
This study aims to evaluate the efficacy and safety of SBRT combined with Puterizumab immunotherapy for non-small cell lung cancer with pulmonary metastases, and to determine the correlation between MRD and treatment efficacy.
- Trial name
- NCT06434740
- Testing
- Stereotactic Body Radiation Therapy，SBRT, Puterizumab
- Volunteers
- 37 people
- Sponsor
- Sir Run Run Shaw Hospital
Multiple Myeloma, Refractory Multiple Myeloma
Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma
Rationale: Giving bortezomib and low doses of chemotherapy and total-body irradiation before a donor stem cell transplant or peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00995059
- Testing
- nonmyeloablative allogeneic hematopoietic stem cell transplantation, allogeneic bone marrow transplantation, bortezomib
- Sponsor
- Mayo Clinic
Non-Hodgkin Lymphoma, Hodgkin Lymphoma
Auto Stem Cell Transplant for Lymphoma Patients
This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.
- Trial name
- NCT03125642
- Testing
- Etoposide, BCNU, AraC
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Colorectal Cancer, Liver Metastases
SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases
To explore the efficacy and safety of stereotactic body radiation therapy (SBRT) combined with PD-1 monoclonal antibody in the treatment of unresectable colorectal cancer liver metastasis through a prospective study, providing…
- Trial name
- SPARKLE-L (NCT06794086)
- Testing
- Stereotactic body radiation therapy, PD-1 Monoclonal Antibody, Chemotherapy
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Jun Huang
Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Haploidentical Hematopoietic Stem Cell Transplantation for Acute Leukemias
This is a prospective observational cohort study of haploidentical transplantation with post-transplant cyclophosphamide for acute leukemias using reduced intensity conditioning for acute myeloid leukemia (AML) and myeloablative…
- Trial name
- NCT02759822
- Testing
- Haploidentical Stem Cell Transplantation
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Leonardo Javier Arcuri
HepatoCellular Carcinoma, Unresectable HepatoCellular Carcinoma
Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma
This study involves a course of radiation to up to 5 tumors in the participant's liver followed by systemic therapy. (Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the…
- Conditions
- HepatoCellular Carcinoma, Unresectable HepatoCellular Carcinoma, Liver Cancer
- Trial name
- NCT02989870
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Sorafenib, Bavituximab
- Where
- United States
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non-Small Cell Lung Cancer
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)
The purpose of this study is to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) plus pembrolizumab (MK-3475) in the treatment of adult participants with unresected Stage I or II (Stage IIB N0, M0)…
- Trial name
- NCT03924869
- Testing
- Stereotactic Body Radiotherapy (SBRT), Pembrolizumab
- Where
- 194 sites in United States, Argentina and 22 more
- Volunteers
- 448 people
- Sponsor
- Merck Sharp & Dohme LLC
Lymphoma
Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver…
- Trial name
- NCT00039195
- Testing
- filgrastim, rituximab, carboplatin
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
5 Fractions of Pelvic SABR With Intra Prostatic SABR Boost:
Stereotactic Ablative Body Radiotherapy (SABR) given in 5 weekly fractions. Simultaneously treating the pelvic lymph nodes, prostate and MRI-nodule to a total dose of 25 Gy, 35 Gy and up to 50 Gy, respectively.
- Trial name
- 5STAR-PC (NCT04245670)
- Testing
- Stereotactic Ablative Body Radiotherapy (SABR) 35-50 Gy/5
- Where
- Canada
- Volunteers
- 75 people
- Sponsor
- Sunnybrook Health Sciences Centre
Head and Neck Neoplasms
STEREO-POSTOP 01 (PostOperative Hypofractionated Stereotactic Body Radiotherapy ) - GORTEC 2017-03
The main objective of this national, open-label, non-randomized phase II trial is to evaluate severe late toxicity of postoperative hypofractionated stereotactic radiotherapy (SBRT) in the treatment of early stage oropharyngeal…
- Trial name
- STEREOPOSTOP (NCT03401840)
- Testing
- postoperative hypofractionated stereotactic radiotherapy
- Where
- 24 sites in France
- Volunteers
- 90 people
- Sponsor
- Centre Jean Perrin
Multiple Myeloma
64Cu-LLP2A for Imaging Multiple Myeloma
The investigators are performing a trial with goals to demonstrate the feasibility of imaging multiple myeloma (MM) patients with 64Cu-LLP2A-positron emission tomography (PET)/magnetic resonance (MR).
- Trial name
- NCT03804424
- Testing
- 64Cu-LLP2A, PET/MR, Blood samples for serum stability
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Metastatic Carcinoma
Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) in One Fraction
This is a multi-site single arm feasibility study of single-fraction Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) for primary or metastatic carcinoma involving the lung, liver, adrenal gland, abdominal/pelvic lymph…
- Trial name
- SMART ONE (NCT04939246)
- Testing
- Stereotactic ablative body radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Baptist Health South Florida
Renal Cell Carcinoma
Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal Tumours
This investigator driven study will examine the safety, efficacy and biological effects of combining pembrolizumab (MK-3475) an antibody targeted against anti-programmed cell death 1 (PD-1), with stereotactic ablative body…
- Trial name
- RAPPORT (NCT02855203)
- Testing
- Stereotactic Ablative Body Radiosurgery (SABR), Pembrolizumab
- Where
- 2 sites in Australia
- Volunteers
- 30 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Bone Calcification, Osteoporosis
Evaluation of Bone Length Measurement
The purpose of this study is to determine if Lunar iXDA scanning with the use of a computer software program can make accurate measurements of the length of leg bones compared to conventional x-rays.
- Trial name
- NCT02165527
- Testing
- Lunar iXDA scan
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Recurrent Non-small Cell Lung Cancer
IR-guided Ablation (IRGA) Combined With Stereotactic Ablative Radiation (SABR) for Large Lung Tumors
This phase I trial studies the side effects and best dose of stereotactic body radiation therapy when given together with ablation therapy in treating patients with non-small cell lung cancer or lung metastases.
- Trial name
- NCT01746810
- Testing
- Stereotactic body RT and IRGA
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- New Mexico Cancer Research Alliance
Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma
This phase I trial studies the side effects and best dose of yttrium Y 90 anti-CD45 monoclonal antibody BC8 when given together with fludarabine phosphate and total-body irradiation followed by donor peripheral blood stem cell…
- Trial name
- NCT01503242
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Fred Hutchinson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.